EGFR and pachyonychia congenita: The oncogenic receptor tyrosine kinase epidermal growth factor receptor (EGFR; encoded by EGFR) is a predictor of sensitivity to anticancer agents and prognosis in patients with PC, and targeting it may suppress the angiogenesis, growth, metastasis, proliferation, and stemness of PC cells and tumors [75–78].